Although several recent clinical trials have demonstrated RTS,S is safe and offers a high degree of protection immediately following vaccination, both the anti-CSP antibody titer and vaccine efficacy against infection wane over time (White et al., 2015; Zavala, 2022). This evidence concerns the gene DNAJC5 and infection.